Medical treatment of Menière’s disease with betahistine:a placebo-controlled, dose-finding study

Klinikum Grosshadern0 个研究点开始时间: 2005年6月15日最近更新: 2015年1月26日

试验速览

暂无简介。

•Definite Ménière’s disease according to the American Academy of Ophthalmology and Otolaryngology, Head and Neck Surgery: Two or more attacks of vertigo, each lasting more than 20 minutes; audiometrically documented hearing loss in at least one examination;tinnitus or aural fullness in the affected ear; other causes excluded.
•Further: at least two attacks of Ménière’s disease per month for at least 3 subsequent months. Age: 18 to 80 yrs; written informed consent to all protocol-specified procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Other vestibular disorders such as vestibular migraine or phobic postural vertigo; contraindications for treatment with betahistine-dihydrochloride, such as asthma bronchiale, pheochromacytoma, pregnancy or breast-feeding, severe dysfunction of kidneys or liver, ulcer of the stomach or duodenum, tumors, severe coronary heart disease, treatment with other antihistamines.

发起方

Klinikum Grosshadern